Literature DB >> 4031878

[3H]Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters.

M M Schweri, P Skolnick, M F Rafferty, K C Rice, A J Janowsky, S M Paul.   

Abstract

Saturable and stereoselective binding sites for [3H]threo-(+/-)-methylphenidate were characterized in rat brain membranes. The highest density of [3H]threo-(+/-)-methylphenidate binding sites was found in the synaptosomal fraction of corpus striatum. Scatchard analysis revealed a single class of noninteracting binding sites with an apparent dissociation constant (KD) of 235 nM and a maximum number of binding sites (Bmax) of 13.4 pmol/mg protein. Saturable, high-affinity binding of [3H]threo-(+/-)-methylphenidate to striatal synaptosomal membranes was dependent on the presence of sodium ions. A good correlation (r = 0.88; p less than 0.001) was observed between the potencies of various psychotropic drugs in displacing [3H]threo-(+/-)-methylphenidate from these sites and their potencies as inhibitors of [3H]3,4-dihydroxyphenylethylamine ( [3H]dopamine) uptake into striatal synaptosomes. A good correlation (r = 0.85; p less than 0.001) was also observed between the potencies of a series of ritalinic acid esters in inhibiting [3H]threo-(+/-)-methylphenidate binding to striatal synaptosomal membranes and their potencies as motor stimulants in mice. These observations suggest that the binding sites for [3H]threo-(+/-)-methylphenidate described here are associated with a dopamine uptake or transport complex, and that these sites may mediate the motor stimulant properties of ritalinic acid esters such as methylphenidate.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031878     DOI: 10.1111/j.1471-4159.1985.tb05524.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  25 in total

1.  Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects.

Authors:  N D Volkow; G J Wang; S J Gatley; J S Fowler; Y S Ding; J Logan; R Hitzemann; B Angrist; J Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

2.  Methylphenidate-induced spontaneous ejaculation.

Authors:  Bedriye Öncü; Burçin Çolak; Okan Er
Journal:  Ther Adv Psychopharmacol       Date:  2015-02

3.  Chronic treatment with extended release methylphenidate does not alter dopamine systems or increase vulnerability for cocaine self-administration: a study in nonhuman primates.

Authors:  Kathryn E Gill; Peter J Pierre; James Daunais; Allyson J Bennett; Susan Martelle; H Donald Gage; James M Swanson; Michael A Nader; Linda J Porrino
Journal:  Neuropsychopharmacology       Date:  2012-07-18       Impact factor: 7.853

4.  Conformational analysis of methylphenidate: comparison of molecular orbital and molecular mechanics methods.

Authors:  Kathleen M Gilbert; William J Skawinski; Milind Misra; Kristina A Paris; Neelam H Naik; Ronald A Buono; Howard M Deutsch; Carol A Venanzi
Journal:  J Comput Aided Mol Des       Date:  2004-11       Impact factor: 3.686

5.  Comparison of characteristics of dopamine uptake and mazindol binding in mouse striatum.

Authors:  I Zimányi; A Lajtha; M E Reith
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

6.  Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: preliminary evidence for different binding domains.

Authors:  C M Dersch; H C Akunne; J S Partilla; G U Char; B R de Costa; K C Rice; F I Carroll; R B Rothman
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

7.  Methylphenidate induces lipid and protein damage in prefrontal cortex, but not in cerebellum, striatum and hippocampus of juvenile rats.

Authors:  Felipe Schmitz; Emilene B S Scherer; Fernanda R Machado; Aline A da Cunha; Bárbara Tagliari; Carlos A Netto; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2012-09-12       Impact factor: 3.584

8.  Conformational analysis of methylphenidate and its structural relationship to other dopamine reuptake blockers such as CFT.

Authors:  M Froimowitz; K S Patrick; V Cody
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

9.  Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice.

Authors:  Aygul Balcioglu; Jia-Qian Ren; Deirdre McCarthy; Thomas J Spencer; Joseph Biederman; Pradeep G Bhide
Journal:  Neuropharmacology       Date:  2009-07-22       Impact factor: 5.250

10.  Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate.

Authors:  T J Volz
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.